A Phase 2 interventional study of ATR-101 in Congenital Adrenal Hyperplasia, sponsored by Millendo Therapeutics, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-10.
Sponsored by Millendo Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Adrenal Hyperplasia, Congenital with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Adrenal Hyperplasia, Congenital · United States.
Among the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, this one is the 27th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2016, is one of 18 in phase 2, and was the 22nd registered.
101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.
Browse Adrenal Hyperplasia, Congenital studies →10 of the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Neurocrine Switzerland GmbH · Sites in United States
Ages 3 mo–47 mo
Johns Hopkins University · Sites in United States
Ages 18+
Crinetics Pharmaceuticals Inc. · Sites in United States, Argentina, Australia and 10 more countries
Ages 1–17
Mayo Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 23 · Phase 3 10 · Phase 4 1
First in 1995; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 37 across 50 interventional studies indexed under Adrenal Hyperplasia, Congenital.
Median enrollment 22 across the 38 interventional studies, 65 across the 11 observational. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 50 have an industry lead sponsor. The 10 most frequent:
Millendo Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Millendo Therapeutics, Inc. has 1 study filed under Adrenal Hyperplasia, Congenital — fewer than ten, so there is no comparison to draw.
2 of the studies in Adrenal Hyperplasia, Congenital with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144163Phase 3Crinetics Pharmaceuticals Inc.A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia | 2027-05 |
| NCT07104812Mayo ClinicImpact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and efficacy of orally administered ATR-101 in subjects with classic congenital adrenal hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to 6 months per subject. A subject may receive a minimum of one dose level or up to a maximum of 5 dose levels, in sequentially increasing dose strengths. Each dose level will last 28 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ascending dose levels of ATR-101 beginning with 125 mg by mouth twice per day up to 1000 mg twice per day.
Drug: ATR-101
125-1000 mg twice per week
Also known as: Nevanimibe hydrochloride
Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101
17-hydroxyprogesterone was measured predose in the morning at the beginning and end of each dose level.
Time frame: Evaluated at baseline and day 15 of each dose level. Each subject will have up to 5 dose levels.
| Milestone | ATR-101 |
|---|---|
| Started | 10 |
| Completed | 9 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
17-hydroxyprogesterone was measured predose in the morning at the beginning and end of each dose level.
| Participants | ATR-101 |
|---|---|
| Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101 | 2 |
Collected over Adverse events were collected from the time the patient signed informed consent until 4 weeks after the last dose of active drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ATR-101 | 0/10 (0%) | 1/10 (10%) | 9/10 (90%) |
| Event | ATR-101 |
|---|---|
| EnteritisGastrointestinal disorders | 1/10 |
| Event | ATR-101 |
|---|---|
| NasopharyngitisInfections and infestations | 4/10 |
| HeadacheNervous system disorders | 4/10 |
| Abdominal pain upperGastrointestinal disorders | 3/10 |
| DiarrhoeaGastrointestinal disorders | 3/10 |
| MigraineNervous system disorders | 3/10 |
| VomitingGastrointestinal disorders | 2/10 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/10 |
| AcneSkin and subcutaneous tissue disorders | 2/10 |
| Atrioventricular block first degreeCardiac disorders | 1/10 |
| DyspepsiaGastrointestinal disorders | 1/10 |
| Age, Continuous(years) | ATR-101 |
|---|---|
| Mean | 30.3 ± 13.76 |
| Sex: Female, Male(Participants) | ATR-101 |
|---|---|
| Female | 5 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | ATR-101 |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | ATR-101 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | ATR-101 |
|---|---|
| United States | 10 |
| 17-hydroxyprogesterone(ng/dL) | ATR-101 |
|---|---|
| Mean | 6591.0 ± 5371.80 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2016 to primary completion in Aug 2017, 14 months.
Results were first posted in Feb 2021, 3 years 6 months after primary completion. A results delay was requested in Oct 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pd-132301 hydrochloride
Adrenal Hyperplasia, Congenital →
Millendo Therapeutics, Inc.